Wednesday 10 December 2014

Ziarco Pharma Ltd - Product Pipeline Review - 2014 - Market Size, Share, Trends, Analysis

Description

Ziarco Pharma Ltd - Product Pipeline Review - 2014

Summary

Global Markets Directs, Ziarco Pharma Ltd - Product Pipeline Review - 2014, provides an overview of the Ziarco Pharma Ltds pharmaceutical research and development focus.

View Full Report At: http://www.marketresearchreports.biz/analysis/235165

This report provides comprehensive information on the current therapeutic developmental pipeline of Ziarco Pharma Ltds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/235165

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ziarco Pharma Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ziarco Pharma Ltds human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ziarco Pharma Ltds pipeline products

Related Reports

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2014

View Full Report At: http://www.marketresearchreports.biz/analysis/220037

The report summarizes all the dormant and discontinued pipeline projects.
A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/220037

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings.

OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma - Opportunity Analysis And Forecast To 2018

View Full Report At: http://www.marketresearchreports.biz/analysis/222341

The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL).

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/222341

Several promising pipeline agents are set to have a dramatic impact on treatment of these relapsed/refractory patients over the forecast period: Pharmacyclics/Janssens Imbruvica, which was approved for relapsed/refractory MCL patients in November 2013, Gileads Zydelig.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

About Us

Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

With a team of experienced consultants we are committed to serve our clients in a way which increase their efficiency, reduce costs and saves time. Our professional search engine helps you in finding the best and latest market research report with just one click of the mouse. Our database represents the most updates and latest market research report collections form all the leading market research publishers across the globe.